Home » Stocks » OSMT

Osmotica Pharmaceuticals PLC (OSMT)

Stock Price: $4.31 USD -0.04 (-0.92%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
After-hours: $4.32 +0.01 (0.21%) Jan 19, 4:31 PM
Market Cap 272.25M
Revenue (ttm) 203.26M
Net Income (ttm) -51.36M
Shares Out 62.79M
EPS (ttm) -0.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $4.31
Previous Close $4.35
Change ($) -0.04
Change (%) -0.92%
Day's Open 4.39
Day's Range 4.31 - 4.52
Day's Volume 297,201
52-Week Range 2.83 - 8.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
24/7 Wall Street - 1 week ago

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: KGC, NDLS, TACO, WIMI
The Motley Fool - 2 weeks ago

One of the company's pipeline candidates ran into a regulatory hurdle.

GlobeNewsWire - 3 weeks ago

BRIDGEWATER, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”...

Benzinga - 3 weeks ago

Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multip...

Other stocks mentioned: AYTU, KNTE, MYOV
GlobeNewsWire - 1 month ago

Adamas to acquire global rights to OSMOLEX ER® for $7.5 million

GlobeNewsWire - 2 months ago

-- Addition of Dr. Raymond Douglas, M.D., PhD, further enhances RVL's commitment to advancing the clinical and scientific platform supporting Upneeq -- -- Addition of Dr. Raymond Douglas, M.D....

GlobeNewsWire - 2 months ago

BRIDGEWATER, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today th...

Seeking Alpha - 2 months ago

Osmotica Pharmaceuticals' (OSMT) CEO Brian Markison on Q3 2020 Results - Earnings Call Transcript

Benzinga - 2 months ago

Shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) rose 4.4% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 148.28% year over year ...

GlobeNewsWire - 2 months ago

Third quarter 2020 total revenue of $57.2 million

GlobeNewsWire - 2 months ago

BRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced th...

GlobeNewsWire - 3 months ago

-- Phase 3 trials showed UPNEEQ was associated with positive outcomes after instillation on days 1 and 14 and was well-tolerated, demonstrating its potential promise for the treatment of acqui...

GlobeNewsWire - 4 months ago

BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today...

Seeking Alpha - 5 months ago

Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 0.00% and -2.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 5 months ago

Shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) decreased 4.46% in after-market trading after the company reported Q2 results.

GlobeNewsWire - 5 months ago

Second quarter 2020 total revenue of $37.5 million

GlobeNewsWire - 5 months ago

-Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO- -Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO-

Zacks Investment Research - 5 months ago

OSMOTICA PHARM (OSMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 5 months ago

OSAKA, Japan and BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd (hereinafter, Santen) and RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuti...

GlobeNewsWire - 5 months ago

BRIDGEWATER, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) through its subsidiary Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a fully ...

The Motley Fool - 6 months ago

The company announced the pricing of a public offering of common stock.

GlobeNewsWire - 6 months ago

BRIDGEWATER, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today ...

GlobeNewsWire - 6 months ago

BRIDGEWATER, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today ...

Benzinga - 6 months ago

Osmotica Pharmaceuticals (NASDAQ: OSMT) surged Friday, ending the day up 25.3% to close at $8.77 per share.

The Motley Fool - 6 months ago

One of the company’s promising products was approved by the FDA.

GlobeNewsWire - 6 months ago

-- First and only FDA-approved pharmacologic treatment for acquired blepharoptosis -- -- Company to host Investor Call at 10:00 a.m. ET today to discuss approval, key elements of the clinical...

GlobeNewsWire - 6 months ago

-- Submission based on world’s largest database of patients treated for spasticity associated with Multiple Sclerosis -- -- Demonstrated efficacy, tolerability and one-year safety results on ...

Zacks Investment Research - 6 months ago

Osmotica Pharmaceuticals (OSMT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

GlobeNewsWire - 7 months ago

BRIDGEWATER, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today ...

PRNewsWire - 7 months ago

BRIDGEWATER, N.J., May 27, 2020 /PRNewswire/ -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, today announced results...

Seeking Alpha - 8 months ago

Osmotica Pharmaceuticals PLC (OSMT) CEO Brian Markison on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 58.33% and 11.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 8 months ago

First quarter 2020 total revenue of $48.6 million

Zacks Investment Research - 8 months ago

OSMOTICA PHARM (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 10 months ago

Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 500.00% and 11.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the st...

Benzinga - 1 year ago

Insider buying can be an encouraging signal for potential investors. Insiders at some small-cap biotechs have made notable share purchases.

Other stocks mentioned: APTX, LJPC
Zacks Investment Research - 1 year ago

OSMT vs. ILMN: Which Stock Is the Better Value Option?

Other stocks mentioned: ILMN
Zacks Investment Research - 1 year ago

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...

Zacks Investment Research - 1 year ago

OSMT vs. QGEN: Which Stock Is the Better Value Option?

Other stocks mentioned: QGEN
Zacks Investment Research - 1 year ago

Osmotica Pharmaceuticals is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Investment Research - 1 year ago

P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.

Other stocks mentioned: CYOU, DBI, NAVI, PWR, SNX
Zacks Investment Research - 1 year ago

Healthcare bounced back with an outperformance starting the fourth quarter.

Other stocks mentioned: BBC, CNCR, GNOM, IHF, IRWD, JNCE, SBIO, SEM
Zacks Investment Research - 1 year ago

OSMT vs. QGEN: Which Stock Is the Better Value Option?

Other stocks mentioned: QGEN
GlobeNewsWire - 1 year ago

--PDUFA date of July 16, 2020-- --PDUFA date of July 16, 2020--

Seeking Alpha - 1 year ago

Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

BRIDGEWATER, N.J., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced...

GlobeNewsWire - 1 year ago

Results from Three Pivotal Phase III Efficacy and Safety Trials (Studies RVL-1201-201, 202 and 203) to Be Presented at Multiple Global Congresses Results from Three Pivotal Phase III Efficacy ...

GlobeNewsWire - 1 year ago

--RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) is a potential first-in-class pharmacologic treatment option for acquired blepharoptosis (droopy eyelid)-- --RVL-1201 (oxymet...

About OSMT

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone, a chlorzoxazone scored tablet for muscle spasms; Con... [Read more...]

Industry
Biotechnology
CEO
Brian A. Markison
Employees
379
Stock Exchange
NASDAQ
Ticker Symbol
OSMT
Full Company Profile

Financial Performance

In 2019, OSMT's revenue was $240.03 million, a decrease of -8.98% compared to the previous year's $263.70 million. Losses were -$270.90 million, 147.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for OSMT stock is "Buy." The 12-month stock price forecast is 8.40, which is an increase of 94.90% from the latest price.

Price Target
$8.40
(94.90% upside)
Analyst Consensus: Buy